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Abstract
Adipose tissue is well-recognized as an endocrine organ which secretes a variety of
bioactive molecules, including angiotensin II and its precursor angiotensinogen (Agt). There is
mounting evidence linking the adipose renin-angiotensin system (RAS) and diet to obesity and
obesity-related disorders. However, research addressing dietary regulation and function of
adipose RAS is limited, and the specific mechanisms by which PUFAs modulate the endocrine
function of adipose tissue remain largely unclear. There are several potential mechanisms that
may mediate PUFA effects on Agt, including toll-like receptor signalling, prostaglandins or
PPAR-gamma. Thus, we propose to investigate whether PUFAs differentially modulate Agt
expression and secretion and to examine possible mechanisms by which PUFA alter Agt
expression using the 3T3-L1 cell line.
Differentiated 3T3-L1 adipocytes were treated with arachidonic acid (AA),
eicosapentaenoic acid (EPA), AA + EPA, or vehicle (C) for 48 hours. Results showed a
significant increase in intracellular Agt protein following treatment with PUFAs. Agt secretion,
however, was only increased by AA. Interestingly, there is a dose-dependent decrease in Agt
protein levels by EPA suggesting that a minimum concentration of n-3 PUFAs is required to
elicit an Agt response. Agt mRNA levels were measured by RT-PCR and results showed a
significant increase in Agt mRNA in response to treatment with AA but not EPA. These findings
suggest that Agt regulation by PUFAs is complex and occurs both post-transcriptionally and
post-translationally.
Changes in mRNA stability may account for the observed effects of PUFAs. Adipocytes
were treated with the transcriptional inhibitor actinomycin D (Act D) and Agt mRNA expression
was measured over time. Total RNA was also measured at each time point to ensure that Act D
treatment was effectively decreasing transcription. Agt mRNA expression was not significantly
altered by treatment with EPA while treatment with AA increased Agt mRNA levels. These
results suggest that Agt mRNA stability is differentially increased by n-6 but not n-3 PUFAs.
Although there are clear effects of AA on Agt secretion and mRNA stability, the signaling
pathways mediating this response remain to be determined, and additional studies are necessary
to further dissect the underlying mechanisms of this regulation.
iv

Table of Contents
Chapter 1: Introduction ................................................................................................................... 1
Chapter 2: Literature Review.......................................................................................................... 3
I. Obesity ................................................................................................................................ 3
A. Incidence and Causes...................................................................................................... 3
B. Adipose Tissue................................................................................................................ 4
II.
Polyunsaturated Fatty Acids ........................................................................................... 5
A. Structure and Metabolism ............................................................................................... 5
B. Eicosanoid Biosynthesis ................................................................................................. 7
C. PUFAs and Obesity......................................................................................................... 9
III.
Renin-Angiotensin System ........................................................................................... 12
A. Systemic/Classic RAS .................................................................................................. 12
B. Local RAS..................................................................................................................... 14
C. Nutritional Regulation of RAS ..................................................................................... 15
IV.
Signaling Pathways Related to Fatty Acid Regulation of Gene Expression ................ 15
A. Insulin Signaling ........................................................................................................... 15
B. TLRs and NF-κB signaling........................................................................................... 16
V. Proposed Mechanisms for the Regulation of Adipose RAS............................................. 18
Chapter 3: Experimental Design and Results ............................................................................... 21
I. Materials and Methods...................................................................................................... 21
A. 3T3-L1 Cell Culture...................................................................................................... 21
B. mRNA stability assay ................................................................................................... 22
C. Western blot analysis .................................................................................................... 22
D. Enzyme-linked immunosorbent assay (ELISA) ........................................................... 23
E. Real-time PCR .............................................................................................................. 24
F. Statistical analysis and data interpretation.................................................................... 25
II.
Results........................................................................................................................... 25
III.
Discussion ..................................................................................................................... 37
Chapter 4: Conclusions and Future Directions ............................................................................. 44
List of References ......................................................................................................................... 46
Appendix....................................................................................................................................... 62
Vita................................................................................................................................................ 79

v

List of Figures
Figure 1: Structures of Saturated and Unsaturated Fatty Acids...................................................... 6
Figure 2: Generation of AA and EPA from Essential Fatty Acids ................................................. 8
Figure 3: Structures of AA and EPA .............................................................................................. 9
Figure 4: Eicosanoid Biosynthesis Pathways and Inhibitors ........................................................ 10
Figure 5: The Renin-Angiotensin System..................................................................................... 12
Figure 6: Proposed Mechanisms for the Regulation of Adipose RAS by PUFAs ....................... 19
Figure 7: Agt Protein Expression in 3T3-L1 Adipocytes Treated with PUFAs ........................... 26
Figure 8: Agt Protein Expression in Culture Media of 3T3-L1 Adipocytes Treated with PUFAs
....................................................................................................................................................... 27
Figure 9: Agt mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs ........................... 29
Figure 10: Dose Response Effects of PUFAs on Agt Protein Expression in 3T3-L1 Culture
Media ............................................................................................................................................ 30
Figure 11: Agt Protein Expression in 3T3-L1 Preadipocytes Treated with PUFAs..................... 31
Figure 12: Agt Protein Expression in Culture Media of 3T3-L1 Preadipocyte Treated with
PUFAs........................................................................................................................................... 32
Figure 13: Ang I Protein Levels in Culture Media of 3T3-L1 Adipocytes Treated with PUFAs 33
Figure 14: Time Course Analysis of Total RNA in 3T3-L1 Adipocytes Treated with PUFAs ... 34
Figure 15: Stability of Agt mRNA in 3T3-L1 Adipocytes Treated with PUFAs......................... 35
Figure 16: TLR4 Protein Expression in 3T3-L1 Adipocytes Treated with PUFAs ..................... 36
Figure 17: TLR4 mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs ..................... 37

vi

Abbreviations
AA
ACC
ACE
ACEi
Act D
ADD1
Agt
ALA
Ang II
ANOVA
aP2
ARB
AT1R
AT2R
BSA
cAMP
cDNA
C/EBP
CEL
COX
cPLA2
C
DEXA
DGLA
DHA
DMEM
DMSO
DNA
EFA
ELISA
EPA
EP R
ERK 1/2
FAS
FBS
GAPDH
GLA
GWA
HETE
HPETE
HSL
IBMX
IKKβ

Arachidonic Acid
Acetyl CoA Carboxylase
Angiotensin Converting Enzyme
Angiotensin Converting Enzyme Inhibitor
Actinomycin D
Alpha-Adducin 1
Angiotensinogen
Alpha-Linolenic Acid
Angiotensin II
Analysis of Variance
Adipocyte Lipid Binding Protein 2
Angiotensin II Receptor Blocker
Angiotensin Type 1 Receptor
Angiotensin Type 2 Receptor
Bovine Serum Albumin
Cyclic Adenosine Monophosphate
Complimentary Deoxyribonucleic Acid
CCAAT/Enhancer Binding Protein
Celecoxib
Cyclooxygenase
Cytosolic Phospholipase A2
Control
Dual Energy X-ray Absorptiometry
Dihomo-γ-Linolenic Acid
Docosahexaenoic Acid
Dulbecco’s Modified Eagle’s Media
Dimethyl Sulfoxide
Deoxyribonucleic Acid
Essential Fatty Acid
Enzyme-Linked Immunosorbent Assay
Eicosapentaenoic Acid
E-Prostanoid Receptor
Extracellular Signal-Regulated Kinases 1 and 2
Fatty Acid Synthase
Fetal Bovine Serum
Glyceraldehyde 3-Phosphate Dehydrogenase
γ-Linolenic Acid
Genome-Wide Association
Hydroxyeicosatetraenoic Acid
Hydroperoxyeicosatetraenoic Acid
Hormone Sensitive Lipase
1-Methyl-3-Isobutylxanthine
IκB Kinase β
vii

IL-1
IL-6
IL-6 R
IRS-1
JNK
LA
LCFA
LOX
LPL
LPS
MAPK
mRNA
MUFA
NF-κB
NSAID
OA
PAI-1
PAMP
PG
PGI
PI3K
PPAR
PRR
P/S
PUFA
LRR
RAS
RIPA
RNA
RXR
RT-PCR
SCD
SDS-PAGE
SOCS3
SREBP1c
STAT3
SVF
T2DM
TBS
TBST
TIR
TLR
TNF-α
WHO
WHR

Interleukin-1
Interleukin-6
Interleukin-6 Receptor
Insulin Receptor Substrate-1
c-Jun Amino-Terminal Kinase
Linoleic Acid
Long Chain Fatty Acid
Lipoxygenase
Lipoprotein Lipase
Lipopolysaccharide
Mitogen-Activated Protein Kinase
Messenger Ribonucleic Acid
Monounsaturated Fatty Acid
Nuclear Factor-κB
Non-Steroidal Anti-Inflammatory Drugs
Oleic Acid
Plasminogen Activator Inhibitor-1
Pathogen-Associated Molecular Pattern
Prostaglandin
Prostacyclin
Phosphoinositide-3 Kinase
Peroxisome Proliferator Activated Receptor
Pattern Recognition Receptor
Penicillin/Streptomycin
Polyunsaturated Fatty Acid
Leucine-Rich Repeat
Renin-Angiotensin System
Radio-Immunoprecipitation Assay
Ribonucleic Acid
Retinoid X Receptor
Real-Time Polymerase Chain Reaction
Stearoyl CoA Desaturase
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
Suppressor of Cytokine Signaling 3
Sterol Regulatory Element Binding Protein 1c
Signal Transducer and Activator of Transcription 3
Stromal Vascular Fraction
Type II Diabetes Mellitus
Tris-Buffered Saline
Tris-Buffered Saline with Tween
Toll/Interleukin-1 Receptor
Toll-Like Receptor
Tumor Necrosis Factor-α
World Health Organization
Waist-to-Hip Circumference Ratio
viii

Chapter 1: Introduction
Obesity has become a worldwide epidemic. The World Health Organization (WHO)
reported in 2005 that globally, at least 400 million adults are considered to be obese, and the
number of overweight or obese children has more than tripled in the last 20 years (59). Excess
body mass is a major risk factor for developing number of diseases, including type II diabetes
mellitus, hypertension, and cardiovascular disease, which is the leading cause of death
worldwide.
Adipose tissue is traditionally thought of solely as the major depot for energy storage.
However, it is now well established that this tissue also acts as an endocrine organ which
secretes bioactive peptides called adipokines (3). An imbalance of these peptides contributes to
obesity and the development of obesity-related disorders via paracrine, autocrine, and endocrine
effects (120). Of specific interest to our lab is the hypertensive hormone Ang II and its precursor
Agt. Ang II secreted from adipocytes has been shown to contribute to circulating plasma Ang II,
which functions in blood pressure regulation (96). Pharmacological blockade of RAS by
angiotensin II receptor blockers (ARB) or ACE inhibitors (ACEi) reduces the anti-adipogenic
effects of Ang II in adipose tissue and prevents diet-induced obesity and insulin resistance (85).
Consequently, Ang II is implicated as being a potentially significant factor in the development of
obesity-related hypertension in conditions of expanded adipose mass.
Research shows that excessive consumption of saturated fat negatively impacts several
biomarkers of health. In contrast, polyunsaturated fatty acids (PUFAs), especially omega-3 (n-3)
PUFAs are considered to be beneficial to human health by reducing adiposity, repressing
lipogenesis and promoting beta-oxidation of fatty acids, as well as by suppressing lipogenic gene
expression in adipocytes (39, 65, 88, 112). Thus, diets rich in PUFAs are able to alter adipose
tissue gene expression and metabolism.
There is mounting evidence linking adipose RAS and diet to obesity and obesity-related
disorders. Indeed, studies indicate that Agt is a fatty acid-responsive gene, and PUFAs increase
Agt expression in a differentiation-dependent manner (110). Further, n-3 and n-6 PUFAs were
shown to modulate adipogenic and lipogenic gene expression in rodent models (39, 65, 88). In
addition, Agt expression is altered in obese versus lean subjects, with most obese animal models
1

having higher expression versus lean counterparts (49, 56, 143). The regulation of gene
expression in adipose tissue may contribute to the beneficial effects of n-3 PUFAs. PUFAs may
alter RAS expression and activity to improve blood pressure and insulin action, and decrease
inflammation. Although studies clearly show that adipose Agt is nutritionally regulated in
parallel with changes in adipogenesis and lipogenesis, it is not known which mechanisms govern
the regulation of Agt gene or protein expression by PUFAs (n-3 and n-6) versus saturated or
monounsaturated fatty acids. Further, there are several potential mechanisms for fatty acid
regulation of Agt in adipocytes, including toll-like receptors (TLRs), peroxisome proliferator
activated receptors (PPARs) or prostaglandins (PGs).
Obesity is associated with chronic low-grade inflammation characterized by an increase
in inflammatory cytokines and adipokines. There is a considerable amount of data linking
proinflammatory cytokine signaling pathways, specifically the toll-like receptor 4 (TLR4)
pathway, to the development of insulin resistance and type 2 diabetes (T2D) in conditions of
expanded adipose mass (124). Further, saturated fatty acids can activate toll-like receptor 4
(TLR4) and TLR2 signaling in adipocytes leading to increased transcription of inflammatory
markers via NF-κB. The prevalence of obesity and the implication of dietary fat in the
development of obesity and obesity-related diseases necessitate a better understanding of the
mechanisms by which specific nutrients influence fat cell function. While data support a
relationship between adipose RAS, inflammation, obesity and diet, the specific mechanisms by
which PUFAs modulate the endocrine function of adipose tissue are largely unclear. Thus, we
propose to investigate whether PUFAs alter Agt expression in adipocytes and the mechanisms by
which this regulation occurs. Elucidation of the mechanisms regulating RAS in adipocytes will
provide a better understanding of the role of dietary fat in the development of obesity as well as
the mechanisms through which specific nutrients influence fat cell function. We hypothesize that
n-3 PUFAs differentially regulate adipose RAS expression and positively alter adipocyte
metabolism, and that mechanisms involved include altered TLRs and/or prostaglandins.
Specifically, our objectives are
1. To determine if PUFAs differentially regulate Agt expression and secretion
2. To investigate mechanisms of regulation of Agt by PUFAs
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Chapter 2: Literature Review
I.

Obesity
A. Incidence and Causes
Obesity has become a worldwide epidemic. More than 1.7 billion people globally are

classified overweight or obese and it has been estimated that this number will rise to
approximately 2.3 billion by 2015 (59). Additionally, the number of overweight or obese
children has more than tripled in the last 20 years. Excess body mass is a major risk factor for
developing a number of metabolic diseases, including type II diabetes mellitus (T2DM),
dyslipidemia, hypertension and cardiovascular disease, which is the leading cause of death
worldwide (29, 52, 82).
Weight status is commonly assessed by body mass index (BMI). BMI is calculated as
weight in kilograms divided by height in meters squared (Table 1). Although an approximation
of fat mass is obtained from BMI, it is only an indicator of weight status. The distribution of fat
in the body is a significant factor in the development of metabolic disorders associated with
obesity. Therefore, direct measurements of body fat can be assessed by skin fold methods or
more accurately by dual energy X-ray absorptiometry (DEXA) for diagnosing weight
abnormalities and determining body composition.
Table 1. Weight Classifications Based on BMI

BMI

Weight Classification

< 18.5

Underweight

18.5 – 24.9

Normal

25 – 29.9

Overweight

30 – 39.9

Obese

> 40

Morbidly Obese
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Obesity is a polygenic disease caused by both gene-gene and gene-environment
interactions. Approximately 40 – 60% of the variation in obesity phenotypes such as BMI, fat
mass and leptin levels is heritable (94, 95, 104, 131). Extensive research has focused on locating
potential susceptibility genes for obesity. Linkage analysis and genome-wide association (GWA)
studies are used to identify and map gene variants that confer disease (116, 119, 150). Numerous
associations between gene variants and obesity have been reported. Environmental factors have
considerable influence on the manifestation of obesity. Indeed, high caloric, unbalanced diet and
sedentary lifestyles are significant contributing factors in the development of obesity and related
disorders.
B. Adipose Tissue
Adipose tissue is traditionally thought of as the major depot for energy storage. However,
it is now well established that this tissue also acts as an endocrine organ that secretes bioactive
peptides called adipokines (3). Experimental data have demonstrated that adipokines are
important regulators of whole-body homeostasis, and an imbalance of these peptides contributes
to obesity and the development of obesity-related disorders via paracrine, autocrine, and
endocrine effects (1, 68, 109).
Adipose tissue is made up of a highly heterogeneous mixture of cells. In addition to
adipocytes, adipose tissue also contains preadipocytes, pericytes, monocytes, macrophages, stem
cells, endothelial cells and vascular smooth muscle cells, which are collectively called the
stromal vascular fraction (SVF) (30). The increase in adipose tissue cytokine expression coupled
with changes in adipose tissue metabolism and endocrine function contribute significantly to the
pathogenesis of the metabolic syndrome associated with obesity.
Excess energy intake increases fat deposition in white adipose tissue. Both adipocyte size
and number increase in parallel with expanding adipose tissue mass (12). Adipocyte hypertrophy
and preadipocyte hyperplasia are associated with abnormalities in adipocyte metabolism and
function leading to an increase in the production and secretion of hormones and proteins from
adipose tissue. Indeed, excessive fat mass is positively correlated with the expression of
proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and
4

interleukin-6 (IL-6). Adipose tissue produces and secretes cytokines and hormones that act via
endocrine effects to influence insulin sensitivity and inflammatory status. Regulation of cytokine
secretion from adipocytes is vital for proper glucose and fat metabolism to occur. Increased
expression of cytokines in adipose tissue decreases insulin sensitivity and increases lipolysis (64).
Visceral fat has been shown to have a greater contribution to the metabolic syndrome
compared to subcutaneous fat (6, 33, 45). Visceral fat secretion of adipokines associated with
systemic inflammation in obese humans (43). Proinflammatory molecules are decreased upon
weight loss while expression of anti-inflammatory molecules increases (23). The expression of
many adipokines is also fat depot-dependent (7, 32). Abnormal regulation of cytokine production
by adipocytes associated with visceral fat accumulation appears to cause dyslipidemia,
hypertension, and glucose intolerance in metabolic syndrome (29). This effect is specific to
visceral fat and is not observed in subcutaneous adipose tissue. A significant positive correlation
between mRNA and protein expression and waist-to-hip circumference ratio has also been
reported in visceral fat (144). Thus, it is evident that excess visceral adipose tissue negatively
impacts whole-body physiology on multiple levels.
II.

Polyunsaturated Fatty Acids
A. Structure and Metabolism
Fatty acids are comprised of a carboxylate head group at the alpha end and long

hydrocarbon chains of varying lengths (Figure 1). Classification of fatty acids is based on the
number of carbons comprising the hydrocarbon chain as well as the degree of unsaturation, or
number of double bonds, and the position of these double bonds. Saturated fatty acids lack
double bonds and are typically linear in structure allowing them to pack together densely.
Monounsaturated fatty acids (MUFAs) contain one double bond and polyunsaturated fatty acids
(PUFAs) contain two or more double bonds. Classification of fatty acids is based on the number
and position of double bonds. EPA has three carbon atoms separating the last double bond from
the terminal methyl (CH3), or the ω carbon, whereas AA has six carbon atoms separating the last
double bond from the ω carbon.
5

Membrane fluidity is largely determined by the fatty acid composition of the
phospholipid bilayer. Unsaturated fatty acids have a lower melting temperature than saturated
fatty acids. The presence of double bonds causes bending of the hydrocarbon chain into either
the cis or trans configuration. Fatty acids cannot pack together and there is a reduction in the
strength of intermolecular forces between fatty acids. This lowers the melting temperature
making the bilayer more fluid. By altering membrane fluidity, fatty acids can directly affect
cellular activity. Changes in the fatty acid composition of membrane phospholipids influence the
structure and fluidity of cell membranes which in turn could alter insulin signaling and
eicosanoid biosynthesis pathways. Indeed, studies show that fatty acid composition is associated
with insulin resistance (134, 145). Saturated fatty acids impair insulin signaling pathways
necessary for glucose uptake resulting in the development of insulin resistance.
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Figure 1: Structures of Saturated and Unsaturated Fatty Acids
6

OH

The majority of the fatty acids are synthesized in the body. Essential fatty acids (EFAs),
however, must be obtained from the diet. There are two classes of EFAs: omega-6 and omega-3
PUFAs. Dietary linoleic acid (LA) is converted into arachidonic acid by a series of desaturation
and elongation steps catalyzed by the enzymes Δ6- and Δ5-desaturases (desaturation), and
elongase (elongation) (Figure 2). Similarly, dietary α-linolenic acid is converted into
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EFAs produce hormones that
regulate numerous metabolic processes such as inflammation and cholesterol metabolism, and
supply the body with energy for cell function.
B. Eicosanoid Biosynthesis
Eicosanoids are generated from the oxidation of LA and ALA. They are functionally
diverse and are invovled in numerous processes such as regulation of blood pressure,
inflammation, immune system modulation, blood clotting, regulation of sleep/wake cycles, and
control of reproductive processes and tissue growth (129).The four major families of eicosanoids
include prostaglandins, prostacyclins, thromboxanes and leukotrienes.
EFAs must be liberated from the membrane in order to synthesize eicosanoids.
Accordingly, AA and EPA are released from the membrane phospholipids by phospholipase A2
(cPLA2). cPLA2 catalyzes the hydrolysis of the ester linkage between the fatty acid and the
glycerol backbone of the lipid bilayer. This is the rate-limiting step for eicosanoid biosynthesis
(80). Free AA is converted into 2-series prostaglandins (PGE2) and free EPA is converted into 3series prostaglandins (PGE3). Cyclooxygenase (COX) catalyzes the oxygenation of AA or EPA
into prostanoids (prostaglandins, prostacyclins and thromboxanes). Similarly, lipoxygenase
(LOX) catalyzes the synthesis of leukotrienes. Eicosanoids generated from EPA decrease
inflammation whereas those from AA promote a proinflammatory state. Because EPA is
structurally similar to AA (Figure 3), it can compete with AA for incorporation into membrane
phospholipids and become the preferential substrate for COX. Oxygenation of AA by COX is
competitively inhibited by n-3 PUFAs and PGE3 is generated instead of PGE2. Indeed, treatment
with pre-formed EPA in the diet decreases PGE2 levels through competitive inhibition of AA
(81). Thus, PGE2 levels can be manipulated by increasing consumption of EPA.
7
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Figure 2: Generation of AA and EPA from Essential Fatty Acids
Linoleic acid (LA) and α-linolenic acid (ALA) undergo a series of desaturation and elongation
steps to generate arachidonic acid (AA) and eicosapentaenoic acid (EPA), respectively.
Desaturation of LA is first catalyzed by Δ6 desaturase to generate γ-linolenic acid (GLA), which
is then elongated via elongase to form dihomo-γ-linolenic acid (DGLA). Desaturation of DGLA
is catalyzed by Δ5 desaturase to yield AA. Similarly, ALA is desaturated first by Δ6 desaturase to
steridonic acid, elongated via elongase to form eicosatraenoic acid (ETA), and then desaturated
again by Δ5 desaturase to generate EPA. Further desaturation of EPA produces docosahexaenoic
acid (DHA).
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Figure 3: Structures of AA and EPA
The chemical structures of AA (n-6) and EPA (n-3) are similar and differ only by the presence of
an extra double bond in EPA. Structural similarities allow EPA to compete with AA for binding
to the COX enzyme.

COX, also known as prostaglandin H2 synthase (PGH2 synthase), has both
cyclooxygenase and peroxidase activity. The COX complex is made up of COX-1 and COX-2
enzymes. COX-1 is constitutively expressed while COX-2 expression is inducible and highly
regulated. Pharmacological inhibition of COX-2 with celecoxib (CEL) decreases PGE2 secretion
in adipocytes, subsequently decreasing lipolysis (148). Corticosteroids are inhibitors of cPLA2
expression thus reducing the amount of AA that is released from the membrane (Figure 4). Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen non-selectively inhibit
both COX-1 and COX-2 activity. Aspirin binds irreversibly to the active site of COX preventing
AA from binding.
C. PUFAs and Obesity
Research shows that excessive consumption of saturated fat negatively impacts several
biomarkers of health. Obesity and metabolic syndrome are positively correlated with saturated
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Figure 4: Eicosanoid Biosynthesis Pathways and Inhibitors
AA is liberated from the membrane by cytosolic phospholipase A2 (cPLA2), converted to PGG2
and PGH2 by cyclooxygenase (COX), and then converted by specific synthases to 2-series
prostaglandins (PG), prostacyclins (PGI), and thromboxanes (TX). Non-steroidal antiinflammatory drugs (NSAIDs) and isoform specific COX inhibitors block eicosanoids
production. AA is also converted to hydroxyeicosatetraenoic acid (5-HETE),
hydroperoxyeicosatetraenoic acid (5-HPETE), and leukotrienes (LT) via lipoxygenase (LOX).
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fatty acid intake (4, 58, 128). However, PUFAs, especially those from the n-3 family, are
considered to be beneficial to human health by reducing adiposity, repressing lipogenesis, and
promoting β-oxidation of fatty acids, as well as suppressing lipogenic gene expression in
adipocytes (39, 65, 88, 112).
PUFAs can alter metabolic processes such as carbohydrate and lipid metabolism. The n-3
family, and to an extent the n-6 family of PUFAs, inhibit lipogenic gene transcription in the liver
as well as in adipose tissue, promoting β-oxidation of fatty acids and repressing lipid synthesis
and storage (6, 67, 112). Thus, there is a shift from lipid synthesis and storage to lipid oxidation.
Dietary n-3 PUFAs act as ligand activators of PPARα, which induces the transcription of genes
invovled in β-oxidation (99). The effects of PUFAs on lipogenic gene expression in adipose
tissue have also been examined. It was found that PUFAs inhibit transcription of lipogenic genes
such as fatty acid synthase (FAS), lipoprotein lipase (LPL), hormone-sensitive lipase (HSL),
adipocyte lipid-binding protein (aP2), and acetyl-CoA carboxylase (ACC), and down-regulate
the enzyme stearoyl-CoA desaturase-1 (SCD1), which catalyzes and regulates the biosynthesis of
monounsaturated fatty acids and whose regulation parallels that of lipogenic enzymes (67, 121).
The regulation of the enzyme SCD1 is physiologically important, and changes in SCD1
activity affect a number of physiological variables such as adiposity, atherosclerosis, and obesity
(140). Inhibitory effects by PUFAs on the expression of SCD1 have been reported in cultured
murine adipocytes (67, 121). These effects may play a central role in the repression of
lipogenesis. SCD1 catalyzes the first regulatory step in the biosynthesis of monounsaturated fatty
acids, which are central components of membrane phospholipids, cholesterol esters, and
triglycerides. PUFAs suppress the production and accumulation of monounsaturated n-9 fatty
acids, such as oleic acid, by inhibiting SCD1 gene expression (67, 122). Our lab previously
demonstrated that PUFAs decrease SCD1 mRNA levels in adipose tissue of both lean and obese
Zucker rats. In addition, we showed that there is a dose-dependent down-regulation of SCD1
expression by PUFAs in mouse 3T3-L1 adipocytes (67). Other studies have reported similar
results using linoleic acid, arachidonic acid, and eicosapentaenoic acid (121). Thus, it is apparent
that diets rich in PUFAs are able to positively alter adipose tissue gene expression and
metabolism.
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III.

Renin-Angiotensin System
A. Systemic/Classic RAS
Classically, the renin-angiotensin system (RAS) is an important regulator of systemic

blood flow and fluid and electrolyte homeostasis. Changes in blood volume stimulate secretion
of the RAS components from various tissues into the bloodstream. Circulating angiotensin II
(Ang II) is the main effector of the renin-angiotensin system (RAS). It is generated from two
enzymatic cleavages of the 452-amino acid precursor angiotensinogen (Agt) by renin and
angiotensin converting enzyme (ACE) (13) (Figure 5). Agt and Ang I can also be cleaved by a
number of other enzymes, including proteases aminopeptidases, carboxypeptidases and
endopeptidases (118). The conversion of Agt to Ang I is the rate-limiting step and an increase in
Agt results in an increase in Ang II synthesis. Ang II acts through the angiotensin type 1 receptor

Angiotensinogen (Agt)
Renin
ACE2

Angiotensin I (Ang I)

ACE

ACE

ACE2

Angiotensin II (Ang II)

AT1 Receptor
Vasoconstriction

Ang (1-9)

Water intake

Ang (1-7)

AT2 Receptor
Sodium reabsorption

Aldosterone release

Net effect: ↑ Blood pressure

Figure 5: The Renin-Angiotensin System
Angiotensinogen (Agt) is cleaved twice, first by renin into angiotensin I (Ang I) and then by
angiotensin converting enzyme (ACE) into angiotensin II (Ang II) to activate RAS. Ang II then
binds to angiotensin type 1 (AT1) or 2 (AT2) receptors. Ang (1-9) and Ang (1-7) are also
produced by ACE2-mediated cleavage of Ang I or Ang II, respectively.
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(AT1R) and angiotensin type II receptor (AT2R) at the cell membrane to exert paracrine and
endocrine effects.
Other biologically active angiotensin peptides have also been identified, including Ang
(1-7) and Ang (1-9) (Table 2). ACE2, a homolog of the ACE enzyme, is the newest component
of the RAS (31, 139). The carboxypeptidase activity of ACE2 produces Ang (1-7) and Ang (1-9)
from Ang II and Ang I, respectively (114) although catalytic efficiency is much greater for Ang
II than Ang I (146). Ang (1-7) opposes the activity of Ang II to regulate blood pressure (40, 41).
Indeed, deletion of ACE2 in mice results in a modest increase in blood pressure and an elevated
response to Ang II (55). Ang (1-7) also has protective effects on cardiac funtion by preventing
cardiac remodeling (42, 115).
The components of the systemic RAS are produced and secreted from different organs
into the circulation where they interact to form bioactive Ang II. Agt is dervied from the liver,
ACE from the vasculature, and renin from the kidneys. However, recent studies have
demonstrated that RAS expression is not limited to the circulation. The RAS components are
also expressed locally in a variety of other tissues, including the brain, heart, prostate, pancreas,
and adipose tissue. The existence of a complete and functional RAS within a tissue or organ
suggests that local RAS may play an important role in whole-body physiology (35, 69, 86).
Table 2. Amino Acid Sequences of Angiotensin Peptides
Angiotensin Peptide

Amino Acid Sequence

Agt

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser

Ang I

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu

Ang II

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Ang (2-8) (Ang III)

Arg-Val-Tyr-Ile-His-Pro-Phe

Ang (1-7)

Asp-Arg-Val-Tyr-Ile-His-Pro

Ang (3-7)

Val-Tyr-Ile-His-Pro

Ang (3-8) (Ang IV)

Val-Tyr-Ile-His-Pro-Phe

Ang (1-9)

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His

Ang (1-12)

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr
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B. Local RAS
Agt secreted from adipose tissue exerts both paracrine and autocrine effects within
adipose tissue. This hormone modulates adipocyte metabolism by increasing adipocyte fatty acid
and triglyceride synthesis via receptor-mediated paracrine effects (28, 68, 75). Our laboratory
demonstrated that mouse, rat and human adipose tissue express several components of the reninangiotensin system, including Agt mRNA and protein (69). This gene was differentially
expressed in lean versus obese Avy/a mice and Zucker rats. In addition, Ang II secreted by
adipose tissue regulates adipocyte metabolism acts via paracrine effects. Ang II induces the
production and secretion of prostacyclin (PGI2), which stimulates lipogenic gene transcription in
a glucose-dependent manner leading to adipocyte differentiation (28, 68). Supportive evidence
has been published by our laboratory demonstrating that the treatment of human adipocytes with
Ang II increases fat synthesis and triglyceride stores (68, 74, 75). Additionally, we have shown
that leptin and FAS gene transcription are up-regulated by Ang II in human adipocytes (68). The
insulin regulatory element (E box) and the Sterol Regulatory Element Binding Protein 1
(SREBP1) mediated the regulation of FAS by Ang II.
Endocrine effects of adipose Ang II have also been demonstrated using engineered mouse
models with targeted inactivation of Agt or with adipose tissue specific expression of Agt (76, 96,
97). These studies provide evidence that adipocyte-derived Agt contributes to circulating Ang II
and is involved in kidney and adipose homeostasis. Genetically engineered mouse models with
targeted overexpression of Agt in adipose tissue exhibit a significant increase in circulating Agt
levels, fat mass and blood pressure compared to wild-type mice (96). Abnormalities in renal
structure and function were observed in Agt-deficient mice, as well as altered expression of
genes that regulate blood pressure and hypotension. However, these changes could be corrected
by re-expressing Agt in adipose tissue, indicating that Agt secreted from adipocytes into the
circulation plays a role in blood pressure regulation (76).
It has also been reported that the inactivation of Agt or one of its receptors (AT1R or
AT2R) prevents high fat diet-induced obesity and insulin resistance in rodents (76, 97, 152). RAS
blockade (via receptor antagonism and ACE inhibition) reduces the incidence of type 2 diabetes,
improve insulin sensitivity and increase circulating adiponectin levels (25, 46, 77). Genetically
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obese rodent models were reported to have much higher Agt expression and secretion after
normalizing to cell size compared to lean littermates (56, 69). Agt may also regulate body fat
distribution; a significant positive correlation between Agt mRNA expression and waist-to-hip
circumference ratio (WHR) was reported in both visceral and subcutaneous adipose tissue in
humans (144). Studies have also shown that weight loss reduces Agt expression in adipose tissue
in humans.
C. Nutritional Regulation of RAS
Adipose Agt is hormonally and nutritionally regulated in response to changes in
adipogenesis and lipogenesis (45, 69). Indeed, adipose Agt has been shown to be regulated by
fatty acids and high-fat feeding (34, 53, 110) as well as by Ang II (93). Expression of Agt in
murine adipocytes was considerably decreased during fasting and elevated upon refeeding (45).
The expression of RAS components in adipose tissue is regulated by fatty acids in a
differentiation-dependent manner (28, 110). Agt expression in preadipocytes was shown to be
responsive to long-chain fatty acids (LCFAs), which act as transcriptional activators (2).
Collectively, these findings suggest that there is a relationship between adipose RAS, obesity and
diet. However, differential regulation of Agt by fatty acids (n-3 versus n-6) has not been
examined in adipocytes.
IV.

Signaling Pathways Related to Fatty Acid Regulation of Gene Expression
A. Insulin Signaling
Insulin is a key hormone in the regulation of glucose metabolism and transport and the

binding of insulin to the insulin receptor (IR) activates signal transduction pathways that regulate
a number of physiological processes. Circulating insulin stimulates glucose transport into tissues
while decreasing gluconeogenesis to regulate blood glucose levels. Insulin also regulates other
physiological processes, including lipogenesis, glycogen synthesis, and cell growth and
differentiation (21).
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The insulin receptor contains an extracellular α-subunit and an intracellular β-subunit.
The β-subunit has tyrosine kinase activity and phosphorylates tyrosine residues of insulin
receptor substrates (IRS). The binding of insulin to the α-subunit of the insulin receptor
stimulates autophosphorylation, which activates the tyrosine kinase activity of the β-subunit.
Subsequently, IRS proteins localize to the cell membrane whereupon they undergo tyrosine
phosphorylation and activation of signal transduction pathways. Signaling is propagated by the
phosphorylation of PI3K leading to GLUT4 translocation and glucose transport, glycogen
synthesis, protein synthesis and cell survival (125). IR signaling pathways are regulated by serine
phosphorylation of IR or IRS proteins, which inhibits tyrosine phosphorylation and,
consequently, the activation of IR signaling pathways.
Insulin resistance often develops as a result of obesity. The effects of fatty acids on
insulin signaling has been well-documented (19, 20, 98, 138, 151). Saturated fatty acids as well
as n-6 PUFAs decrease tyrosine phosphorylation of IRS-1 (44). Substitution of fish oil into a
high-fat diet improves insulin action in rats (127). The renin-angiotensin system also interferes
with insulin signaling and action. Indeed, pharmacological inhibition of RAS improves insulin
sensitivity (22). Ang II secreted from adipocytes activates phosphoinositide-3 kinase (PI3K)mediated insulin signaling via receptor-mediated paracrine effects (77).
B. TLRs and NF-κB signaling
Inflammatory pathways of the innate immune system are activated by the recognition of
microbial structures called pathogen-associated molecular patterns (PAMPs) by toll-like
receptors (TLRs) (66). Currently, 13 families of TLRs have been identified and characterized in
mice, 11 of which have also been identified in humans (149). All TLRs are type I transmembrane
proteins with a cytoplasmic carboxy-terminal Toll/Interleukin-1 receptor (TIR) domain and an
extracellular amino-terminal leucine-rich repeat (LRR) domain. These pattern recognition
receptors (PRRs), which are classified by their ligand specificity, are integral to innate immunity;
the capacity of the TLRs to respond to the highly diverse PAMPs of viruses, gram-negative and
gram-positive bacteria, fungi and parasites (113) enables the eukaryotic host to reliably detect
microbial infections. Thus, it is not surprising that the TLRs are ubiquitously expressed on the
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surface (TLRs 1, 2, 4, 5 and 6) or in the interior (TLRs 3, 7, 8 and 9) of a variety of immune cells,
including monocytes, macrophages, dendritic cells and neutrophils (36) as well as non-immune
cells like vascular endothelial cells, lung and intestinal epithelial cells, cardiac myocytes and
adipocytes (5). The recognition of PAMPs by their respective TLRs activates the innate immune
system.
TLR4 is a pattern recognition receptor which is specifically activated by
lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria, resulting in
increased production of proinflammatory cytokines. TLR4 is expressed in adipocytes and is
highly responsive to bacterial LPS in humans (8, 90). Accordingly, human adipocytes contain a
high concentration of proinflammatory cytokines (90). The discovery of immune cells, including
monocytes, macrophages and leukocytes, in the stromal vascular fraction (SVF) of adipose tissue
led to the hypothesis that the majority of the inflammatory responses in adipose tissue are not
due to adipocytes but rather these immune cells. Whether adipose tissue macrophages or
adipocytes can differentially activate TLR4 has yet to be established. In humans, TLR4
expression and activity in adipocytes is comparable to that of monocytes (8). The response of
TLR4 in adipocytes is as sensitive as that of TLR4 in immune cells. The presence of functional
TLR4 in adipose tissue and increased production and secretion of proinflammatory cytokines
from adipose in conditions of expanded fat mass suggest a potentially significant role of this
pathway in the development of obesity-induced inflammation and insulin resistance.
Nuclear factor-kappa B (NF-κB) regulates cellular immune responses to microbial
infection by modulating the production proinflammatory cytokines such as IL-2, IL-1 and TNF-α
(51, 111). The regulation of immune responses by NF-κB is crucial for preventing chronic
activation of proinflammatory pathways. IKKβ is also implicated in the development of insulin
resistance. It phosphorylates IκB causing proteasomal degradation, which liberates NF-κB
allowing it to translocate into the nucleus and activate the transcription of cytokines. NF-κB is
activated by both the mitogen-activated protein kinase (MAPK) and phosphoinositide-3
kinase/Akt (PI3K/Akt) pathways, and activation promotes the expression of genes whose
products cause insulin resistance (126).
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V.

Proposed Mechanisms for the Regulation of Adipose RAS
Dietary fatty acids are able to alter adipose tissue gene expression and metabolism.

PUFAs are beneficial to a number of metabolic processes. A dose-dependent hypotensive effect
of n-3 PUFAs was reported in humans (107). They also improve insulin sensitivity and decrease
inflammation associated with obesity. Agt and Ang II are also nutritionally regulated. However,
research addressing PUFA regulation of RAS in adipose tissue is limited and the mechanisms by
which this may occur are unclear.
Several mechanisms may mediate the effects of PUFAs on Agt in adipocytes (Figure 6).
One possibility is that prostaglandins mediate this regulation. PGE2 and PGI2 are produced from
AA and have been shown to increased inflammation. They also exert paracrine/autocrine effects
on adipocytes (78). Ang II induces the production and secretion of prostacyclin (PGI2) from
mature adipocytes, which stimulates lipogenic gene transcription in a glucose-dependent manner
resulting in adipocyte differentiation (28). Low dose PUFAs supplemented in the diets of healthy
adults resulted in a decrease in prostaglandin E1 and leukotriene B4 secretion (72, 106). Thus,
the effects of PUFAs on Agt in adipocytes may be mediated by changes in prostaglandin levels.
PPARγ plays a central role in regulating adipogenesis. It binds to the promoter and
activates the transcription of many lipogenic and adipogenic genes (141). The beneficial effects
of n-3 PUFAs on adipogenesis, lipolysis, inflammation and apoptosis could involve the
inhibition of PPARγ gene expression (100). However, other studies report that n-3 PUFAs
stimulate adipogenesis by interacting with PPARγ (79, 92). PUFAs are able to bind directly to
PPARs and modulate the expression and activity of lipogenic or lypolytic genes, and this is a
potentially confounding factor in determining the role of PPARs in regulating genes.
Continuous activation of the innate immune system often develops from obesity.
Increasing evidence supports a potentially significant role of the innate immune system in the
etiology of obesity-related metabolic diseases via inflammatory signaling pathways, specifically
the toll-like receptor 4 (TLR4) signaling pathways. TLR signaling leads to the translocation of
NF-κB into the nucleus where it increases transcription of proinflammatory cytokines, including
IL-6 and TNF- as well as COX-2. IL-6 and TNF-α induce serine phosphorylation of IRS which
blocks insulin receptor signaling. The abnormal regulation of cytokine production by adipocytes
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Figure 6: Proposed Mechanisms for the Regulation of Adipose RAS by PUFAs
PGE2 and PGI2 are generated from AA and subsequently secreted by adipocytes. They
then bind to EP receptors at the surface of the cell and stimulate adipocyte differentiation (PGI2).
EPA competitively inhibits the generation of PGE2 and PGI2 from AA to produce PGE3 and
PGI3. PPARs bind a number of substrates, including FFA, Akt, and ERK 1/2. PUFAs are able to
directly bind to PPARs and modulate lipogenic and lypolytic genes. NF-κB is activated by TLR4
signaling and subsequently translocated into the nucleus where it regulates IL-6 and TNF-α gene
transcription. IL-6 and TNF-α bind to receptors their respective receptors and activate signaling
via STAT3 and JNK and SOCS3 leading to serine phosphorylation of IRS-1 and the disruption
of insulin signaling. Ang II secreted from adipocytes regulates fat cell metabolism in part by
modulating PI3K-mediated insulin signaling. It also increases PGI2 resulting in increased
adipocyte differentiation.
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is associated with visceral fat accumulation and appears to cause dyslipidemia, hypertension, and
glucose intolerance. Recently, saturated fat was shown to activate TLR4 and TLR2 signaling in
adipocytes leading to increased production of proinflammatory cytokines (117). Conversely, n-3
PUFAs have been shown to decrease inflammation by blocking TLR-stimulated upregulation of
proinflammatory cytokines (83, 84). Ang II activates many of the same pathways as TLR4.
However, it is not know whether TLRs can mediate the effects of PUFAs on Agt expression in
adipocytes.
The NF-κB signaling pathway has been implicated in development of obesity-related
insulin resistance because it activates the transcription of proinflammatory cytokines that are
known to interfere with insulin signaling and action (26). TLR4 signaling activates NF-κB,
which is subsequently translocated into the nucleus where it regulates transcription of a number
of genes, including TNF-α, IL-6, IL-1 and COX-2. Insulin resistance presumably develops from
the disruption of insulin signaling by these proinflammatory cytokines. IL-6 and TNF-α bind to
the appropriate receptors and activate signaling. Activated IL-6 and TNF-α induce the
phosphorylation of serine residues on IRS-1 thereby disrupting insulin receptor signaling.
Whether regulation of Agt by PUFAs is mediated by insulin signaling pathways is not known.
The purpose of this study was to determine whether fatty acids differentially regulate
adipocyte Agt expression and secretion in 3T3-L1 adipocytes, and to investigate possible
mechanism(s) mediating this regulation. We hypothesize that n-3 PUFAs will differentially
modulate adipose RAS expression and positively alter adipocyte metabolism, and that
mechanisms involved include altered TLRs and/or prostaglandins.
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Chapter 3: Experimental Design and Results
I.

Materials and Methods
A. 3T3-L1 Cell Culture
3T3-L1 preadipose cells were obtained from the American Type Culture Collection

(ATCC, Manassas, VA) and were cultured in regular growth media consisting of Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1%
Penicillin-Streptomycin (P/S). Confluent cells were differentiated into adipocytes by treatment
with 0.5 mM 1-methyl-3-isobutylxanthine (IBMX), 0.25 μM dexamethasone and 10 nM insulin
(Humulin R®, Eli Lily) for 2 days and then were maintained in regular growth media.
Differentiation was considered complete 5-7 days after confluence with ~80-95% of the cells
being differentiated. 24 hours prior to treatment, growth media was changed to starvation media
consisting of serum-free DMEM with 1% (w/v) fatty acid-free Bovine Serum Albumin (BSA)
(Sigma-Aldrich, St. Louis, MO) and 1% P/S.
Cell culture experiments commonly use BSA to bind and stabilize free fatty acids to
prevent oxidation as well as to act as a carrier for the fatty acids, which are insoluble in water (18,
54). In addition, albumin binds and transports circulating free fatty acids in vivo making it
physiological relevant to use BSA conjugated fatty acids (57). Fatty acids were solubilized in
dimethyl sulfoxide (DMSO) and then conjugated to fatty acid-free BSA by agitation in a 37°C
water bath for 2 hours prior to treatment. Fatty acid treatment media consisted of serum-free
DMEM plus 1% fatty acid-free BSA, 1% P/S, 10 nM insulin and specific treatment (fatty acid or
vehicle). Previous dose-response studies indicated that 150 μM AA or EPA (Nu-Check Prep, Inc.,
Elysian, MN) produced maximal effects on Agt gene expression and Ang II secretion without
being toxic to the cell (148). Cells were treated with 150 μM AA, 150 μM EPA, 150 μM
AA+EPA (75 μM of each fatty acid), or vehicle (DMSO) for 48 hours.
A dose-response study was previously performed (148). Briefly, 3T3-L1 adipocytes were
cultured and differentiated, and EPA and AA were prepared as described above. Differentiated
cells were separated into treatment groups and received either 50 μM, 100 μM, 200 μM, or 500
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μM of fatty acid (EPA or AA) or vehicle (DMSO). Following 48 hours of treatment, cells were
harvested for protein or RNA and stored at -80ºC for future use.
B. mRNA stability assay
Gene expression can be regulated by the stability of the mRNA. The amount of protein
that is produced depends on the turnover rate of the corresponding mRNA. Cells were
differentiated and treated with fatty acids as described above. Following fatty acid treatment, 1ml
of media was collected before the media was aspirated off and then new treatment media was
added. The transcriptional inhibitor Actinomycin D (Act D) (Sigma-Aldrich, St. Louis, MO) was
added (10 μg/ml) to treated cells as previously reported (24, 27, 70, 133). 1ml of media was
collected and cells were harvested in 600 μl of Qiazol lysis buffer at 0, 4, 12 and 24 hours after
Act D addition. Total RNA was extracted from these cells and converted into cDNA for
subsequent analysis. Agt mRNA abundance was measured by RT-PCR as described below.
C. Western blot analysis
Cells were harvested in 300 μl of radio-immunoprecipitation assay (RIPA) buffer
containing a protease inhibitor cocktail and homogenized for 5 minutes on ice. Protein
concentration was measured by Bradford assay using Coomassie G-250 Dye (Thermo Fisher
Scientific Inc, Rockford, IL) (11). Normalized protein (30 g) was separated by SDS-PAGE gel
electrophoresis at 100 V using a 10% Tris-HCl gel (Bio-Rad, Hercules, CA). Proteins were
transferred to a nitrocellulose membrane at 70 V for 3 hours at 4°C with a stir bar. To evaluate
transfer efficiency, membranes were stained with Ponceau S (Thermo Fisher Scientific Inc,
Rockford, IL). Gels were stained with Coomassie Brilliant Blue R-250 staining solution and
destained overnight at 4°C using Coomassie Brilliant Blue R-250 destaining solution (Bio-Rad,
Hercules, CA) to verify that protein transfer was successful.
Non-specific binding was blocked using 5% non-fat dry milk (NFDM) in Tris-Buffered
Saline (TBS) (Bio-Rad, Hercules, CA) containing 0.1% Tween (TBST) (Fisher, Pittsburgh, PA).
Primary antibodies from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA)
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included the following: rabbit polyclonal anti-ACE2, anti- AT1R, anti- AT2R, anti-GAPDH, antiPPARγ, anti-PAI-1, anti-phospho-Akt, anti-IRS-1, and anti-vitronectin; goat polyclonal anti-Agt,
anti-Renin, anti-TLR2, anti-TLR4, anti-COX-1, and anti-COX-2; and mouse polyclonal anti-Akt.
Primary antibodies obtained from Millipore (Billerica, MA) included mouse monoclonal antiACE and rabbit polyclonal anti-adiponectin. Horseradish peroxidase-conjugated anti-rabbit IgG,
anti-mouse IgG and anti-goat IgG secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA).
To visualize proteins, chemiluminescence was performed using SuperSignal West Pico
(Thermo Fisher Scientific Inc, Rockford, IL). GAPDH was used as a loading control for cell
lysates and vitronectin was used as a loading control for culture media. Relative intensity was
quantified by densitometry using ImageQuant TL v2005 software (GE Healthcare Biosciences,
Piscataway, NJ). Background was subtracted from the protein of interest (POI) and then band
volume intensities were divided by the area to obtain normalized values. The ratio of normalized
POI to normalized loading control was calculated to allow for comparisons. Protein expression
fold change was determined for each treatment relative to the control.
D. Enzyme-linked immunosorbent assay (ELISA)
ELISAs are a highly sensitive, robust method frequently used to quantitate proteins in
culture media or serum (101). It has a wide dynamic range and is able to detect low levels of
protein with high sensitivity and minimal little background. Differential expression and secretion
of Agt, Ang I, adiponectin, TNF-α and IL-6 in response to treatment with PUFAs was examined
by ELISA. Culture media and cells were harvested in RIPA and sonicated as described above.
Commercially available ELISA kits for Agt (Immuno-Biological Laboratories Co., Ltd.,
Minneapolis, MN), Ang I (Phoenix Pharmaceuticals, Inc., Burlingame, CA), adiponectin (Linco
Research, Billerica, MA), TNF-α and IL-6 (ALPCO Diagnostics, Salem, NH) were used to assay
samples following the manufacturer’s protocol. Specific protein concentrations were calculated
based on a standard curve generated in each assay.
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E. Real-time PCR
The use of real-time polymerase chain reaction (RT-PCR) for mRNA quantitation
eliminates the electrophoresis step of traditional Northern blot methods, providing fast, sensitive,
and accurate measurements. This methodology has been well-developed and standardized and is
commonly used to measure mRNA levels. Gene-specific primers are used to amplify a portion of
the gene of interest. A fluorescently-labeled probe binds specifically to the DNA as it is
amplified, allowing for continuous quantitation of the amount of amplicon being produced over a
period of time. A reporter dye binds new copies of double-stranded DNA. As the amount of
amplicon being produced accumulates, the fluorescence intensity increases proportionately. Thus,
fluorescence intensity gives an indication of gene expression.
The direct effect of fatty acids on adipocyte mRNA expression were examined in control
and fatty acid treated 3T3-L1 cells. Following treatment, cells were harvested in 600 μl of Qiazol
lysis reagent (Qiagen, Valencia, CA). Samples were separated by centrifugation at 13000 rpm for
30 mins at 4°C. Total RNA was extracted from adipocytes using the RNeasy mini kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. RNA concentrations and quality and
integrity of the RNA were assessed using a NanoDrop (Thermo Fisher Scientific Inc, Rockford,
IL). Isolated RNA was then reverse transcribed to cDNA using the Superscript First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Specific mRNA was quantitated from
diluted cDNA (1:10) by real-time PCR using the ABI Prism 7000 Sequence Detection System
and ABI Prism 7000 SDS software (Applied Biosystems, Carlsbad, California). RT2 Real-Time
SYBR Green (SABiosciences, Frederick, MD) was used as the reporter dye. PCR was performed
for 40 cycles. Relative mRNA expression was calculated using the 2–ΔΔCt comparative threshold
cycle method, as previously described (91). β-actin was used as an internal standard to normalize
expression data.
Primer sequences for renin, ACE, adiponectin, COX-1, COX-2, PPARγ, TLR1, TLR2,
TLR4 and β-actin were obtained from PrimerBank
(http://pga.mgh.harvard.edu/primerbank/index.html) (132, 147) (Table 3). Primers were ordered
from Sigma Genosys (Sigma-Aldrich, St. Louis, MO). Primers for Agt, AT1R, AT2R and FAS
were a generous gift from Dr. Brynn Voy (Oak Ridge National Laboratory, Oak Ridge, TN).
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Table 3. Primer Sequences for RT-PCR
Gene
ACE
Agt
AT1R
AT2R
β-actin
COX-1
COX-2
FAS
PPARγ
Renin
TLR1
TLR2
TLR4

PrimerBank ID
33468873a1
n/a
n/a
n/a
6671509a3
6679537a2
31981525a1
n/a
6755138a3
13676837a1
13507603a1
31981333a2
10946594a2

Forward Primer (5’→3’)

Reverse Primer (5’→3’)

AGGTTGGGCTACTCCAGGAC

GGTGAGTTGTTGTCTGGCTTC

CGGAGGCAAATCTGAACAAC

GTCGGCTGTTCCTCCTCTC

AATGGCTGGCATTTTGTCTG

GCTTTTCTGGGTTGAGTTGG

GCCTGCATTTTAAGGAGTGC

TGCAGCAACTCCAAATTCTT

AGTGTGACGTTGACATCCGTA

GCCAGAGCAGTAATCTCCTTCT

CTGTTGTTACTATCCGTGCCAG

CTCAGGGATGGTACAGTTGGG

TGAGCAACTATTCCAAACCAGC

GCACGTAGTCTTCGATCACTATC

GGAGGTGGTGATAGCCGGTAT

TGGGTAATCCATAGAGCCCAG

TGTGGGGATAAAGCATCAGGC

CCGGCAGTTAAGATCACACCTAT

CTCTCTGGGCACTCTTGTTGC

GGGAGGTAAGATTGGTCAAGGA

TGAGGGTCCTGATAATGTCCTAC

AGAGGTCCAAATGCTTGAGGC

ACAATAGAGGGAGACGCCTTT

AGTGTCTGGTAAGGATTTCCCAT

GCCTTTCAGGGAATTAAGCTCC

AGATCAACCGATGGACGTGTAA

F. Statistical analysis and data interpretation
Data analysis was performed in SAS 9.2 (SAS Institute, Inc, Cary, NC). Gene expression
data and protein fold change values were evaluated for nutrient effects by Student’s unpaired t
test. Time course data were analyzed using orthogonal polynomial contrasts. Dose response data
were analyzed by factorial analysis of variance. Descriptive statistics (mean ± SEM) and
comparative statistics were obtained by one-way ANOVA and were used to analyze total RNA.
Tukey’s test was used for post-hoc analysis when significance was detected. P < 0.05 was
considered statistically significant for all tests. Data are reported as the mean ± SEM.
II.

Results

Effect of PUFAs on Agt expression in 3T3-L1 cells and culture media
Agt protein expression was examined in 3T3-L1 cell lysates and corresponding culture
media following treatment with PUFAs. Results from these experiments show a significant
increase in intracellular Agt in response to treatment with PUFAs (P < 0.001) (Figure 7). Agt
secretion into the media is consistently increased by treatment with AA (P < 0.001) (Figure 8).
25

C

AA

A+E

EPA

75

Agt

50
GAPDH

3.5

*

Agt (Fold Change)

3
2.5

*

*

2
1.5
1
0.5
0
C

AA

EPA

A+E

Figure 7: Agt Protein Expression in 3T3-L1 Adipocytes Treated with PUFAs
Western blot is representative of 8 different blots from 3 independent experiments. Lanes 1 and 2,
Control (C); Lanes 3 and 4, AA (150 μM); Lanes 5 and 6, EPA (150 μM); Lanes 7 and 8, A+E
(150 μM AA+EPA). GAPDH was used as a loading control. The approximate molecular weight
of Agt is 60 kD and GAPDH is 37 kD. The graph shows relative fold change of Agt expression
in treated cells vs control. n = 16 for all treatments. * P < 0.001 vs control.
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Figure 8: Agt Protein Expression in Culture Media of 3T3-L1 Adipocytes Treated with
PUFAs
Western blot is representative of 5 different blots from 3 independent experiments. Lanes 1 and 2,
Control (C); Lanes 3 and 4, AA (150 μM); Lanes 5 and 6, EPA (150 μM); Lanes 7 and 8, A+E
(150 μM AA+EPA). Vitronectin was used as a loading control. The approximate molecular
weight of Agt is 60 kD and vitronectin is 75 kD. The graph shows relative fold change of Agt
expression in treated cells vs control. n = 10 for all treatments. * P < 0.001 vs control.
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This effect was prevented by treatment with EPA. These findings indicate that Agt is
differentially regulated by PUFAs and that treatment with n-6 PUFAs increase Agt protein
expression and secretion while n-3 PUFAs cause Agt to be retained in the cell. Three repetitions
of fatty acid treatments with 150 μM AA, EPA, AA+EPA, or vehicle in 3T3-L1 adipocytes were
performed to verify the reproducibility of these results. Indeed, these effects were explicitly
reproduced in all three replicate experiments.
mRNA expression levels were also measured following fatty acid treatment to examine
the effects of PUFAs on mRNA content. RT-PCR was performed using RNA isolated from 3T3L1 cells treated with 150 μM AA, EPA, AA+EPA or vehicle. Results show that treatment with
AA increases Agt mRNA expression compared to the control (P < 0.0001) (Figure 9).
Conversely, treatment with EPA or combined treatment with AA and EPA did not significantly
alter Agt mRNA levels.
A dose response study with PUFAs (AA and EPA) was previously performed by our lab
and these samples were used to assess dose effects of PUFAs on Agt protein expression.
Differentiated 3T3-L1 cells were treated with 50 μM, 100 μM, 200 μM, or 500 μM of AA or
EPA for 48 hours. Agt protein expression was measured in cell lysates and culture media as
described in the Materials and Methods section. There was a trend toward increased Agt
secretion with increasing doses of AA (Figure 10). Interestingly, treatment with increasing doses
of EPA appeared to decrease Agt secretion although statistical significance was not reached.
Cell Specific effects of PUFAs on Agt expression
To eliminate the possibility that the effects of PUFAs on Agt expression and secretion are
due to preadipocytes, 3T3-L1 preadipocytes were treated with 150 μM AA, 150 μM EPA,150μM
AA+EPA or vehicle (DMSO). Agt protein expression was assessed in cell lysates and culture
media using differentiated adipocytes treated with vehicle as a positive control. As expected, Agt
expression was not detected in preadipocyte cell lysates (Figure 11) or culture media (Figure
12) but was detected in the positive control sample
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Figure 9: Agt mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
Agt mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average relative
expression values from 3 independent RT-PCR experiments. n = 4 for C, AA and A+E; n = 3 for
EPA. * P < 0.01 vs control.
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Figure 10: Dose Response Effects of PUFAs on Agt Protein Expression in 3T3-L1 Culture
Media
Western blot is representative of 2 different blots. Vitronectin was used as a loading control. The
approximate molecular weight of Agt is 60 kD and vitronectin is 75 kD. The graph shows
relative fold change of Agt expression in treated cells vs control. n = 2 for all treatments.
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Figure 11: Agt Protein Expression in 3T3-L1 Preadipocytes Treated with PUFAs
Agt expression was assessed in preadipocytes treated with 150 μM AA, 150 μM EPA, 150 μM
AA+EPA (A+E) or vehicle (C). Mature adipocytes treated with PUFAs served as a positive
control for Agt expression. Lanes 1 and 2, Control (C); Lanes 3 and 4, AA; Lanes 5 and 6, EPA;
Lanes 7 and 8, A+E; Lane 9, Positive Control (+C). GAPDH was used as a loading control for
cell lysates. The approximate molecular weight of Agt is 60 kD and GAPDH is 37 kD. n = 2 for
C, AA, EPA and A+E; n = 1 for +C. A.U., arbitrary units.
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Figure 12: Agt Protein Expression in Culture Media of 3T3-L1 Preadipocyte Treated with
PUFAs
Agt expression was assessed in the culture media of preadipocytes treated with 150 μM AA, 150
μM EPA, 150 μM AA+EPA (A+E) or vehicle (C). Mature adipocytes treated with PUFAs served
as a positive control for Agt expression. Lanes 1 and 2, Control (C); Lanes 3 and 4, AA (150
μM); Lanes 5 and 6, EPA (150 μM); Lanes 7 and 8, A+E (150 μM AA+EPA); Lane 9, Positive
Control (+C). Vitronectin was used as a loading control for media. The approximate molecular
weight of Agt is 60 kD and vitronectin is 75 kD. n = 2 for C, AA, EPA and A+E; n = 1 for +C.
A.U., arbitrary units; Vitro, vitronectin.
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Effect of PUFAs on Ang I levels in 3T3-L1 cells and culture media
The cleavage of Agt into Ang I by the enzyme renin is the rate-limiting step of the RAS
pathway. It is possible that the increased secretion of Agt in response to AA is a secondary result
of decreased renin activity causing less Agt to be cleaved. Thus, renin activity was indirectly
assessed by measuring Ang I levels. Ang I protein levels in the cell and media were measured as
an indication of renin activity. Treatment with AA increased Ang I secretion into the culture
media (P < 0.001) (Figure 13). However, Ang I levels were undetectable in cell lysates
indicating that levels intracellular levels of Ang I are very low, likely reflecting rapid secretion of
Ang I and/or rapid intracellular conversion of the majority of Ang I into Ang II.
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Figure 13: Ang I Protein Levels in Culture Media of 3T3-L1 Adipocytes Treated with
PUFAs
Ang I protein levels were measured the culture media treated with 150 μM AA, 150 μM EPA,
150 μM AA+EPA (A+E) or vehicle (C) to assess renin activity in response to PUFAs. n = 8 for
all treatments. * P < 0.001 vs control.
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Effect of PUFAs on Agt mRNA stability and half-life
The stability of mRNA can significanly affect gene expression and subsequently cell
growth, differentiation and activity. PUFAs may differentially regulate Agt mRNA stability.
Cells were treated with the antibiotic actinomycin D, which inhibits cell proliferation. Total
RNA was measured for each time point (0 hours, 4 hours, 12 hours and 24 hours) to assess the
degradation of RNA by actinomycin D over time (Figure 14). A decrease in total RNA
concentration was determined for each of the treatments suggesting that transcription was in fact
inhibited by the actinomycin D. To assess the stability of Agt mRNA, Agt mRNA expression
levels were also assessed as a function of time (Figure 15). Agt levels were determined as a
percentage prior to the addition of actinomycin D. Treatment with EPA did not significantly alter
Agt mRNA levels. Treatment with AA, however, significantly increased Agt mRNA levels at 4

RNA (μg/μl)

hours (P < 0.0001) and 24 hours (P < 0.05).
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Figure 14: Time Course Analysis of Total RNA in 3T3-L1 Adipocytes Treated with PUFAs
Total RNA was measured in adipocytes treated with PUFAs. The graph represents total RNA
levels at 0 hrs, 4 hrs, 12 hrs and 24 hrs following the treatment of actinomycin D (10 μg/ml). C
(■), AA (150 μM) (○), EPA (150 μM) (▲). n = 6 for C; n = 5 for AA and EPA.
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Figure 15: Stability of Agt mRNA in 3T3-L1 Adipocytes Treated with PUFAs
Agt mRNA levels were measured in triplicate in adipocytes treated with PUFAs at 0 hrs, 4 hrs,
12 hrs and 24 hrs following the treatment of actinomycin D (10 μg/ml). The graph represents the
average expression values from 2 independent RT-PCR experiments. C (■), AA (○), EPA (▲). n
= 7 – 9 for each treatment at each time point. * P < 0.05 vs control; * P < 0.0001 vs control.
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TLR expression and signaling as a potential mechanism of Agt regulation
It is possible that the effects of PUFAs on Agt expression is mediated by TLR signaling.
To investigate this possibility, TLR4 protein and mRNA expression were measured. Intracellular
protein expression of TLR4 was significantly elevated in adipocytes treated with AA or EPA
compared to the control (P < 0.05) (Figure 16). Conversely, TLR4 mRNA levels were
significantly decreased by AA (P < 0.05) and EPA (P < 0.05 ) treatments and a trend for
decreased TLR4 by combined treatment with AA and EPA (P < 0.06 ) (Figure 17).
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Figure 16: TLR4 Protein Expression in 3T3-L1 Adipocytes Treated with PUFAs
Western blot is representative of 3 different blots. Lanes 1 and 2, Control (C); Lanes 3 and 4, AA
(150 μM); Lanes 5 and 6, EPA (150 μM); Lanes 7 and 8, A+E (150 μM AA+EPA). GAPDH was
used as a loading control. The approximate molecular weight of TLR4 is 89 kD and GAPDH is
37 kD. The graph shows the relative fold change of TLR4 expression in treated cells vs control.
n = 6 for all treatments. * P < 0.05 vs control.
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Figure 17: TLR4 mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
TLR4 mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C).. The graph represents the average relative
expression values from 2 independent RT-PCR experiments. n = 4 for C, AA and A+E; n = 3 for
EPA. * P < 0.05 vs control.

III.

Discussion
Research addressing the dietary regulation of the renin-angiotensin system (RAS) in

adipose tissue by polyunsaturated fatty acids (PUFAs) is limited. However, numerous lines of
evidence suggest that there is a correlation between adipose RAS, diet, obesity and obesityrelated disorders. For example, Agt expression is altered in obese subjects compared to their lean
counterparts, with most obese animal models showing higher Agt expression. Agt is also
differentially expressed in visceral versus subcutaneous tissue and higher expression levels are
present in visceral fat. Further, some PUFAs suppress lipogenic gene expression in adipose
tissue and may consequently alter the expression of other adipocyte genes. Studies also indicate
that treatment of adipocytes with PUFAs increases Agt expression in a differentiation-dependent
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manner. Collectively, these findings suggest that there is a relationship between adipose RAS,
obesity and diet.
While previous studies convincingly support a relationship between adipose RAS,
obesity and diet, the specific mechanisms of these interactions are largely unknown. To
determine if PUFAs differentially regulate Agt expression in adipocytes, protein and mRNA
expression levels were measured in 3T3-L1 adipocytes treated with AA, EPA, AA + EPA, or
vehicle and their corresponding culture media. Treatment with PUFAs resulted in an increase in
intracellular Agt regardless of which fatty acid they were treated with. Further, the n-6 PUFA
arachidonic acid (AA) selectively increased Agt secretion into culture media. Interestingly,
treatment with increasing doses of EPA appeared to decrease Agt secretion into the media
although statistical significance was not reached. This suggests that the beneficial effects of n-3
PUFAs may be dose-dependent. RT-PCR data indicate that AA significantly increases Agt
mRNA expression while EPA does not.
Transcription is a major step in the regulation of gene expression. Transcriptional
regulation typically involves the interaction of several transcription factors, which bind to target
DNA sequences. Agt expression may be regulated by fatty acids at the transcriptional level.
Long-chain fatty acids were shown to increase Agt expression in murine preadipocytes by a
PPAR-mediated process (110). Adipogenic factors are usually required for terminal
differentiation of preadipocytes into adipocytes. However, even in the absence of these factors,
fatty acids are still effectively able to activate gene expression, eliminating the possibility that
the observed effects of fatty acids are due to differentiation. To determine if PUFAs regulate Agt
expression, Agt mRNA levels were measured. Increased Agt mRNA and increased intracellular
Agt protein suggests there is an increased production of the RAS precursor which becomes
selectively secreted. Expression of the other RAS components, including ACE (Appendix,
Figure A1), renin (Appendix, Figure A2), AT1R (Appendix, Figure A3)and AT2R (Appendix,
Figure A4), were also evaluated and results are summarized in the appendix.
To the best of our knowledge, this is the first study showing increased Agt secretion in
adipocytes treated with AA. Increased Agt secretion by n-6 PUFAs but not n-3 PUFAs implies
that fatty acids differentially regulate adipose RAS. The ability of PUFAs to differentially
regulate Agt is significant. Numerous studies have shown that increases in adipose RAS
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expression is linked to obesity-related hypertension in humans and in rodents (10, 15, 16, 34, 50,
96, 105, 143). Moreover, it has been suggested that the balance of n-3 to n-6 PUFAs is important
for normal physiology and development. Increased intake of n-6 PUFAs coupled with a decrease
in n-3 PUFA intake results in the generation of high levels of n-6 derived eicosanoids, including
prostaglandins (PGs), thromboxanes, leukotrienes and lipoxins. Large quantities of these
eicosanoids induce a prothrombotic state (128). Importantly, secretion mechanisms were not
examined to determine if they are differentially modulated by PUFAs. Previous studies have
investigated Agt secretion mechanisms in adipocytes (142). However, the effects of PUFAs were
not examined. Thus, it is possible that changes in protein synthesis and secretion rate account for
the differential effects of PUFAs on Agt in adipocytes.
Preadipocytes are inevitably present even after differentiation, though only in very small
amounts. To eliminate the possiblity that the observed results are due to preadipocytes and not to
PUFA effects, Agt protein expression was examined in preadipocytes treated with PUFAs. As
expected, Agt was detected in mature adipocytes treated with vehicle, which was used as a
positive control, but was not detected in preadipocytes. Accordingly, the effects of PUFAs on
Agt secretion is not due to preadiocytes.
The cleavage of Agt into Ang I is the rate-limiting step of the RAS pathway. Increased
Agt secretion in response to AA could be a secondary result due decreased renin activity, which
would result in decreased conversion of Agt into Ang I and, thus, increased secretion of
uncleaved Agt. To determine if renin activity is altered by AA, Ang I protein levels were
measured in cell lysates and their corresponding culture media following treatment with PUFAs.
Renin levels in the media were significantly increased by AA, which may indicate that there is
an increase in renin transcription and activity in response to n-6 PUFAs. However, intracellular
renin could not be detected likely due to rapid secretion of Ang I and/or rapid intracellular
conversion of Ang I into Ang II. Other studies have indicated that although renin expression has
been detected in adipose tissue, renin enzymatic levels have not been consistently demonstrated
(48, 71, 103).
Increased Agt mRNA levels by AA may be due to increased transcription. However, it
may also be due to increased stability of Agt mRNA. Theoretically, the rate of specific
transcription, processing, or turnover can modulate mRNA concentration. Gene regulation is
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often achieved through the modulation of mRNA stability. Previous studies have shown that
mRNA stability can be modulated by PUFAs in adipocytes. SCD1 gene expression is inhibited
by PUFAs via decreased mRNA stability (121). Specifically, treatment with AA decreased the
half-life of SCD1 mRNA. A similar study in adipocytes showed that GLUT4 mRNA stability is
also reduced by treatment with AA (137). To determine if the regulation of adipocyte Agt gene
expression by PUFAs is achieved through changes in message stability, total RNA and Agt
mRNA levels were assessed over time following the addition of a transcriptional inhibitor,
actinomycin D. PUFA-treated adipocytes were subsequently treated with the transcriptional
inhibitor, actinomycin D. As expected, total RNA was decreased by both PUFA treatments.
Treatment with EPA decreased mRNA stability of Agt while overall, AA increased stability.
These findings indicate that n-6 PUFAs differentially stabilize Agt mRNA and provides one
possible mechanism by which AA regulates Agt.
It has been demonstrated that TLR4 can regulate energy intake and expenditure as well as
mediate cross-talk between the inflammatory and metabolic pathways (60, 73, 135). Indeed,
TLR4 expression and activity are higher in the adipocytes and macrophages of high fat dietinduced obese, genetically obese (ob/ob) and diabetic (db/db) mice compared to wild-type
littermates (12, 14, 130). TLR4 expression has been shown to localize on the surface of immune
cells as well as adipocytes where it binds to bacterial lipopolysaccharide (LPS) and induces
nuclear factor-kappa B (NF-κB) translocation into the nucleus resulting in an increase in the
transcription of proinflammatory cytokines such as IL-6, TNF-α and COX-2 (37, 89, 102, 136).
Recently, it was shown that there is an increase in TLR4 protein expresion following treatment
with saturated or monounsaturated fatty acids (117). Significantly, the authors did not measure
the effects of PUFAs on TLR4 expression. Our results show for the first time that TLR4 protein
expression is significantly increased by both AA and EPA PUFAs. This suggests that fatty acids
may increase the production of cytokines via activation of TLRs. Importantly, changes in
downstream signaling activity were not measured. It is possible that although expression of
TLR4 is increased by PUFAs, signaling may be attenuated.
The increase in TLR4 expression by both n-3 and n-6 PUFAs may be due to nonspecific
activation by all fatty acids. Although statistically significant, the changes in TLR4 protein levels
were subtle. It is possible that an LPS challenge is necessary to ellicit a greater response in TLR4
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expression as it is the ligand activator. Indeed, stimulation with LPS significantly increased
TLR2 expression in preadipocytes compared to unchalleged preadipocytes (Claycombe, et al.,
unpublished data).
Interestingly, we found that TLR4 and TLR2 (Appendix, Figure A5) mRNA levels were
decreased by PUFAs. Other studies have reported similar results in LPS-treated porcine
adipocytes (47). This may represent increased translation of TLR4 into protein although it
remains possible that the decrease is a nonspecific effect of fatty acids.
TNF-α can directly modulate lipid metabolism and glucose homeostasis (61, 63, 123). It
has been shown to stimulate lipolysis in adipocytes and induce insulin resistance and is directly
regulated by NF-κB (64). TNF-α is associated with obesity and insulin resistance and is
upregulated in obese individuals. Indeed, obese subjects exhibit extremely high amounts of TNFα, especially in adipose tissue (62). Significant increases in TNF-α impair insulin sensitivity
presumably through the phosphorylation of serine residues and subsequent deactivation of IRS-1.
The alteration of adipokine expression profiles by TLR4 and TLR2 has been implicated
as a potential mechanism for fatty acid-induced inflammation and insulin resistance. Indeed,
activation of PKC, NF-κB and MAPK signaling pathways lead to increased cytokine production
and an inflammatory state in 3T3-L1 adipocytes (20). In mice, palmitate caused greater
production of TNF-α and IL-10 in adipocytes compared to OA and DHA (21). To assess the
downstream effects of PUFAs on TLR4 signaling, TNF-α and IL-6 intracellular protein and
secretion levels were measured. TNF-α levels were undetectable in the media and were not
significantly different in the cell compared to the control (Appendix, Figure A6). Similarly, IL6 protein levels in the cell (Appendix, Figure A7) and in the media (Appendix, Figure A8)
were not significantly changed in response to PUFA treatment.
Peroxisome proliferator activated receptors (PPARs) are members of the nuclear receptor
superfamily. They are major regulators of adipocyte differentiation. PPARγ is a ligand activated
transcription factor. Alternative splicing of PPARγ gives two forms. PPARγ1 is widely
expressed by a number of different cell types whereas PPARγ2 is exclusively expressed in
adipocytes. PPARγ heterodimerizes with other proteins, including (C/EBP) and 9-cis-retinoic
acid receptor (RXR), and this complex binds to response elements within the promoter of target
genes to regulate transcriptional activity. Numerous studies have shown that PPAR proteins have
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an affinity for PUFAs (9, 79). Indeed, PUFAs are able to bind directly to PPARs and modulate
the expression and activity of lipogenic or lypolytic genes such as ADD1/SREBP1c, cAMP
response element (CREB) and GATA-binding transcription factors (i.e. GATA2, GATA3) (9).
PPARs were recently shown to have anti-inflammatory effects in adipose tissue.
Activation of PPARγ by PUFAs decreases phosphorylation of IκB, which then inhibits NF-κB
signaling and the subsequent production of proinflammatory cytokines (87, 100). Thus, the antiobesity effects of n-3 PUFAs may be due to decreased PPARγ expression (108). However, this
remains controversial as other studies have reported induction of PPARγ expression by n-3
PUFAs and stimulation of adipogenesis (17, 79, 92). Our results show that PPARγ protein
expression is significantly increased by AA (Appendix, Figure A9). Although statistical
significance was not reached, treatment with EPA appears to decrease PPARγ protein expression.
Thus, PPARγ cannot be eliminated as a potential mediator of PUFA regulation of Agt.
Importantly, future studies should take into consideration that PUFAs can bind and activate
PPARs, and this is a potentially confounding factor in determining the role of PPARs.
Arachidonic acid is converted into 2-series prostaglandins (PGE2) and prostacyclins
(PGI2) by the cyclooxygenase complex (COX) and then secreted by adipocytes. Prostoglandins
are ligands for the EP receptors present on the cell surface and can act in an autocrine or
paracrine manner to increase PGE2 generation from AA. Adipose tissue secretion of PGE2
increases FAS enzyme activity and decreases lipolysis in obese individuals by decreasing cAMP
levels, and this is mediated through interaction with EP3 receptors (38). The result is an increase
in endogenous fatty acid production. EPA competitively inhibits the generation of PGE2 from
AA and the 3-series prostaglandins (PGE3) are produced instead. Studies have shown that many
of the beneficial effects of PUFAs are mediated by changes in PG levels. Indeed, COX-2 protein
expression was inhibited by PUFAs but potentiated by saturated fat via TLR-mediated NF-κB
signaling in mouse monocytes (83). Therefore, PUFA regulation of Agt may be mediated by PGs.
COX-1 and COX-2 mRNA expression were examined in PUFA-treated adipocytes. COX-1
(Appendix, Figure A10) and COX-2 (Appendix, Figure A11) mRNA levels were significantly
decreased by AA. The significance of this is unclear, however, as COX-1 and COX-2 protein
expression were not examined.
To further examine the role of PGs, adipocytes previously treated with the COX-2
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inhibitor celecoxib (CEL) were used to assess Agt protein expression in cell lysates (Appendix,
Figure A12) and corresponding culture media (Appendix, Figure A13) following treatement
with fatty acids. Consistent with previous results, Agt secretion was significantly increased by
AA (P < 0.001) and decreased by EPA (P < 0.0001) in media samples.
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Chapter 4: Conclusions and Future Directions
The purpose of this study was to determine whether fatty acids differentially modulate
Agt expression and secretion and to investigate possible mechanism(s) mediating the regulation
of adipose RAS in 3T3-L1 adipocytes. We hypothesized that n-3 PUFAs would differentially
regulate adipose RAS expression and positively alter adipocyte metabolism, and that
mechanisms involved include altered TLRs and/or prostaglandins. Our results are as follows:
1. n-6 but not n-3 PUFAs increase Agt secretion in 3T3-L1 adipocytes.
2. Agt protein levels increase with increasing doses of AA and decrease with increasing
doses of EPA.
3. Regulation of Agt secretion is not specific to adipocytes and not due to preadipocytes
but may be attributed to changes in renin activity.
4. PUFAs increase mRNA expression of RAS components, especially Agt in AAtreated cells.
5. n-6 PUFAs increase Agt mRNA stability while n-3 PUFAs do not.
6. TLR2 and TLR4 protein expression are both increased by PUFAs.
Significantly, results indicated that treatment with n-3 and n-6 PUFAs increase
intracellular Agt while n-6 PUFAs, but not n-3 PUFAs, differentially increase Agt secretion.
These effects appear to be dose-dependent as Agt protein levels increased with increasing doses
of AA but decreased with increasing doses of EPA. Decreased secretion of Agt by n-3 PUFA
further supports the beneficial effects of n-3 fatty acids in metabolic disorders and cardiovascular
health. Regulation of Agt by PUFAs was not an effect of preadipocytes but may be due in part to
changes in renin activity. Secretion mechanisms were not investigated in this study and should
be addressed in future studies. It is important to dissect the mechanisms of secretion to
understand why n-6 PUFAs differentially increase secretion while n-3 PUFAs do not.
Results also showed that PUFAs increase mRNA expression of RAS components,
including Agt, ACE and renin, with AA having the greatest effect on Agt expression. In addition
to regulating transcription, AA also increases Agt mRNA stability while EPA does not. Thus, it
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appears that mechanisms of regulation of Agt by PUFAs are complex. Future studies are needed
to clarify the mechanisms mediating PUFA effects on Agt in adipocytes and to identify putative
transcription factors involved in transcriptional regulation.
TLR4 protein expression was increased by PUFAs suggesting that it may be involved in
the regulation of adipocytes. Importantly, we did not stimulate cells with LPS, which may
account for the low TLR protein expression levels that were observed. Thus, stimulation of
PUFA-treated adipocytes with LPS is necessary for examinations of TLR expression in
adipocytes as a possible mediator of Agt regulation. In order to better understand whether TLR
signaling is involved in PUFA regulation, downstream signaling molecules should be
investigated, including PI3K and NF-κB. Though we examined IL-6 and TNFα cytokines in this
study, it may be useful to perform multiplex cytokine analysis to better understand how the
inflammatory response is altered by PUFAs in adipocytes. Numerous lines of evidence support a
role for innate immunity in the development of obesity-related inflammation and insulin
resistance and this remains an interesting and novel area of research, particularly in adipocytes.
Preliminary studies were conducted to address other potential mechanisms that may
mediate PUFA regulation of Agt in adipocytes such as PPARs or prostaglandins. We were
unable to obtain consistent results for PPARs using existing samples. It seems likely that this was
due to sample quality and studies should be repeated. PPAR agonists and antagonists can be used
to facilitate investigations of the role of PPARs in Agt regulation. PPARs are able to bind to a
variety of substrates making it difficult to draw conclusions. Consequently, experiments should
be carefully designed with this in mind. Treatment studies with the COX-2 inhibitor celecoxib
and PUFAs and the subsequent examination of Agt will facilitate further investigation of the role
of prostaglandins in mediating Agt regulation by PUFAs.
While additional experiments are clearly needed to further dissect the mechanisms
mediating regulation of Agt and other RAS genes by PUFAs, our studies demonstrate for the
first time that n-6 PUFAs specifically increase Agt secretion while n-3 PUFAs decrease secretion.
These findings support the beneficial effects of n-3 fatty acids in metabolic disorders and
cardiovascular health.
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Introduction
Several mechanisms may mediate the effects of PUFAs on Agt in adipocytes. One
possibility is that prostaglandins mediate this regulation. Studies have shown that many of the
beneficial effects of PUFAs are mediated by changes in PG levels. PPARγ plays a central role in
regulating adipogenesis and may also be involved in PUFA regulation of Agt. Further, increasing
evidence supports a potentially significant role of the innate immune system in the etiology of
obesity-related metabolic diseases via inflammatory signaling pathways, specifically the toll-like
receptor 4 (TLR4) signaling pathways. Indeed, Ang II activates many of the same pathways as
TLR4. However, it is not know whether TLRs can mediate the effects of PUFAs on Agt
expression in adipocytes. Thus, additional experiments were performed to further investigate
potential mechanisms underlying the regulation of Agt by PUFAs. Related findings have also
been referenced in the discussion section of this thesis.
Materials and Methods
Samples were obtained from treatment studies previously performed by our lab using the
COX-2 inhibitor celecoxib (CEL) or PUFAs (148). Briefly, 3T3-L1 preadipocytes were cultured
and differentiated as described above. 24 hours prior to treatment, starvation media was added.
Fatty acids were solubilized in dimethyl sulfoxide (DMSO) and then conjugated to fatty acidfree BSA by agitation in a 37°C water bath for 2 hours prior to treatment. Cells were treated with
5 μM Celebrex (CEL) (Pharmacia, St. Louis, MO), 150 μM OA, 150 μM AA, 150 μM EPA, 150
μM AA+EPA (75 μM of each fatty acid), or vehicle (DMSO) for 48 hours.
Results
The effects of PUFAs on Agt (thesis main results) as well as other RAS components were
assessed in adipocytes. There were increased ACE mRNA levels in EPA-treated cells (P < 0.05)
(Figure A1). Renin mRNA expression was not significantly different in treated versus control
cells (Figure A2). AT1R mRNA levels were significantly decreased in cells treated with EPA
compared to the control (P < 0.05) (Figure A3). AT2R mRNA levels were decreased by all
PUFA treatments (P < 0.05) (Figure A4).
TLR2 can also bind fatty acids and activate the same pathways as TLR4. Thus, TLR2
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was assessed in PUFA-treated adipocytes. The effects of PUFAs on TLR2 mRNA expression
appears to be differential and AA decreases TLR2 (P < 0.01) while EPA and AA+EPA do not
significantly alter levels (Figure A5). To assess whether the increase in TLR4 protein expression
has an effect on downstream events, intracellular and secreted TNF-α and IL-6 were measured
by ELISA. Intracellular TNF-α levels were not significantly different from control treated
samples (Figure A6) and were undetectable in the media. Similarly, both intracellular IL-6
(Figure A7) and IL-6 secretion (Figure A8) in PUFA-treated samples were similar to the control.
PUFAs can bind directly to PPARγ and alter lipogenic or lipolytic gene expression
resulting in decreased inflammation. To determine if the beneficial effects of n-3 PUFAs on Agt
are mediated by PPARγ, protein and mRNA levels were measured. Unexpectedly, PPARγ
protein expression was significantly increased by AA (P < 0.05) but unchanged by EPA or
combined treatment with AA + EPA (Figure A9).
The COX enzyme complex catalyzes the first step in the generation of prostaglandins,
prostacyclins and thromboxanes. PUFA regulation of Agt in adipocytes may be mediated by
prostaglandin levels. Thus, COX-1 and COX-2 expression and activity were examined in
adipocytes treated with PUFAs. COX-1 mRNA (P < 0.05) (Figure A10) and COX-2 mRNA (P
< 0.01) (Figure A11) levels were both decreased by treatment with AA.
To investigate whether prostaglandins mediate the effects of PUFAs on Agt, adipocytes
were treated with CEL, OA, AA, EPA, or vehicle. Agt protein expression in cell lysates (Figure
A12) and media samples (Figure A13) following treatment was examined. Consistent with
previous results, Agt secretion was significantly decreased in media samples from cells treated
with EPA and significantly increased by treatment with AA. Effects on intracellular Agt were
inconclusive, likely due to sample degradation. The effects of the COX-2 inhibitor celecoxib
(CEL) on Agt expression were also inconsistent and further studies are needed.
Adiponectin is an important marker of insulin sensitivity and in general adiponectin
levels are inversely related to adiposity. The effects of PUFAs on insulin sensitivity were
assessed by measuring adiponectin secretion. Treatment with CEL significantly increased
adiponectin secretion (P < 0.05) (Figure A14). In contrast, adiponectin secretion was
significantly decreased by treatment with AA (P < 0.001). Decreased adiponectin by AA
suggests an increased risk for obesity and insulin resistance by n-6 PUFAs but not n-3 PUFAs.
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Figure A1. ACE mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
ACE mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 3 independent RT-PCR experiments. n = 4 for C; n = 3 for AA, EPA and A+E. * P
< 0.05 vs control.
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Figure A2. Renin mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
Renin mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 3 independent RT-PCR experiments. n = 4 for C, AA and A+E; n = 3 for EPA.
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Figure A3. AT1R mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
AT1R mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 2 independent RT-PCR experiments. n = 4 for C, AA and A+E; n = 3 for EPA. * P
< 0.05 vs control.
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Figure A4. AT2R mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
AT2R mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 3 independent RT-PCR experiments. n = 4 for C, AA and A+E; n = 3 for EPA. * P
< 0.05 vs control.
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Figure A5. TLR2 mRNA Expression in 3T3-L1 Adipocytes Treated with PUFAs
TLR2 mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150 μM
EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 2 independent RT-PCR experiments. n = 4 for C; n = 3 for AA, EPA and A+E. * P
< 0.01 vs control.
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Figure A6. TNF-α Protein Levels in Culture Media of 3T3-L1 Adipocytes Treated with
PUFAs
TNF-α protein levels were measured in the culture media of adipocytes treated with 150 μM AA,
150 μM EPA, 150 μM AA+EPA (A+E) or vehicle (C). n = 6 for all treatments.
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Figure A7. IL-6 Protein Levels in 3T3-L1 Adipocytes Treated with PUFAs
IL-6 protein levels were measured in adipocytes treated with 150 μM AA, 150 μM EPA, 150 μM
AA+EPA (A+E) or vehicle (C). n = 6 for all treatments.
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Figure A8. IL-6 Protein Levels in Culture Media of 3T3-L1 Adipocytes Treated with
PUFAs
IL-6 protein levels were measured in the culture media of adipocytes treated with 150 μM AA,
150 μM EPA, 150 μM AA+EPA (A+E) or vehicle (C). n = 8 for all treatments.
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Figure A9. PPARγ Protein Expression in 3T3-L1 Adipocytes Treated with PUFAs
PPARγ protein expression was assessed in cell lysates in response to treatment with 150 μM AA,
150 μM EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph shows relative fold change of
PPARγ expression in treated cells vs control. n = 4 for all treatments. * P < 0.05 vs control.
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Figure A10. COX-1 mRNA Expression Levels in 3T3-L1 Adipocytes Treated with PUFAs
COX-1 mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150
μM EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 3 independent RT-PCR experiments. n = 4 for C; n = 3 AA, EPA and A+E. * P <
0.05 vs control.
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Figure A11. COX-2 mRNA Expression Levels in 3T3-L1 Adipocytes Treated with PUFAs
COX-2 mRNA levels were measured in triplicate in adipocytes treated with 150 μM AA, 150
μM EPA, 150 μM AA+EPA (A+E) or vehicle (C). The graph represents the average expression
values from 3 independent RT-PCR experiments. n = 4 for C; n = 3 AA, EPA and A+E. * P <
0.01 vs control.
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Figure A12. Agt Protein Expression in 3T3-L1 Adipocytes Treated with PUFAs
Agt protein expression was assessed in adipocytes treated with 5 μM Celecoxib (CEL), 150 μM
OA, 150 μM AA,150 μM EPA or vehicle (C). The graph shows relative fold change of Agt
expression in treated cells vs control. n = 6 for all treatments. * P < 0.01 vs control.
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Figure A13. Agt protein expression in Culture Media of 3T3-L1 Adipocytes Treated with
PUFAs
Agt protein expression was assessed in the culture media of adipocytes treated with 5 μM
Celecoxib (CEL), 150 μM OA, 150 μM AA,150 μM EPA or vehicle (C). The graph shows
relative fold change of Agt expression in treated cells vs control. n = 10 for C; n = 4 for CEL and
OA; n = 14 for AA; n = 9 for EPA. * P < 0.001 vs control; ** P < 0.0001 vs control.

77

500

*

450
Adiponectin (ng/ml)

400

**

350
300
250
200
150
100
50
0
C

CEL

OA

AA

EPA

A+E

Figure A14. Adiponectin Protein Levels in Culture Media of 3T3-L1 Adipocytes Treated
with PUFAs
Adiponectin protein levels were measured in the culture media of adipocytes treated with 5 μM
Celecoxib (CEL), 150 μM OA, 150 μM AA,150 μM EPA, A+E (150 μM AA+EPA) or vehicle
(C). n = 10 for all treatments. * P < 0.05 vs control; ** P < 0.001 vs control.

Summary
Potential mechanisms mediating the regulation of Agt by PUFAs were examined,
including TLRs, PPARγ, or prostaglandins. Other RAS components were also assayed to provide
a comprehensive evaluation of adipose RAS expression and activity in response to treatment
with PUFAs. While preliminary data was obtained from these experiments, additional studies are
needed to clarify the role of these mechanisms in mediating PUFA regulation of Agt in
adipocytes.
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